Scholarlink

Background <p>Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and Türkiye.</p> Methods <p>Medical records (2010–2011) of patients (≥ 18&#xa0;years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT).</p> Results <p>Of 1511 patients analyzed (median age: 59.5&#xa0;years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common first- and second-line treatments; lenalidomide-based regimens were common in later lines. Median TTNT from initiation of first-line treatment was 39.5&#xa0;months. Only 31.7% of patients received SCT at diagnosis, with improved outcomes versus those without SCT (median overall survival: 114.1 vs 85.9&#xa0;months; 5-year relapse-free rates after first-line treatment: 58.2% vs 49.3%).</p> Conclusion <p>Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment pathways and clinical outcomes in newly diagnosed multiple myeloma outside Europe and North America: The INTEGRATE study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月15日

查看全文
  • Kihyun Kim,
  • Estelle Verburgh,
  • Tatiana Mitina,
  • Wenming Chen,
  • Su-Peng Yeh,
  • Natalia Schutz,
  • Fahad Alsharif,
  • Wee Joo Chng,
  • Zhongwen Huang,
  • Meral Beksac

摘要

Background

Real-world data on multiple myeloma (MM) outside Europe and North America are limited. The INTEGRATE study retrospectively assessed real-world treatment pathways and outcomes in MM from Argentina, China, South Korea, South Africa, Russia, Saudi Arabia, Taiwan, and Türkiye.

Methods

Medical records (2010–2011) of patients (≥ 18 years) with newly diagnosed MM were analyzed. The primary endpoint was time to next treatment (TTNT). Secondary endpoints included treatment pathways and clinical outcomes stratified by stem cell transplantation (SCT).

Results

Of 1511 patients analyzed (median age: 59.5 years), 32% had IgG kappa MM and 35.9% had International Staging System stage III disease. Bortezomib- and thalidomide-based chemotherapy regimens were the most common first- and second-line treatments; lenalidomide-based regimens were common in later lines. Median TTNT from initiation of first-line treatment was 39.5 months. Only 31.7% of patients received SCT at diagnosis, with improved outcomes versus those without SCT (median overall survival: 114.1 vs 85.9 months; 5-year relapse-free rates after first-line treatment: 58.2% vs 49.3%).

Conclusion

Treatment strategies for MM outside Europe and North America align with guideline recommendations. More effective treatments and SCT at treatment initiation are needed. This study can guide future research in these regions utilizing newer treatment options.